[Basic and clinical study of meropenem in pediatric field]

Area of Science:

• Pharmacology
• Infectious Diseases
• Pediatric Medicine

Background:

• Meropenem (MEPM) is a novel parenteral carbapenem antibiotic.
• A cooperative study was conducted across 12 pediatric and 1 neonatologic facilities to evaluate MEPM.
• Existing antibiotics like imipenem, cefazolin, cefotiam, cefotaxime, ceftazidime, and latamoxef served as controls.

Purpose of the Study:

• To assess the antibacterial activity of meropenem against a range of bacterial strains.
• To evaluate the pharmacokinetic properties of meropenem in pediatric patients.
• To determine the clinical efficacy of meropenem in treating infections.

Main Methods:

• Antibacterial activity was determined by Minimum Inhibitory Concentrations (MICs) against stock and clinical isolates.
• Pharmacokinetic parameters were assessed via plasma concentrations, half-life, and urinary excretion rates after intravenous infusion in children.
• Clinical efficacy was evaluated in 49 pediatric cases.

Main Results:

• MEPM exhibited potent activity against Gram-positive and Gram-negative bacteria, with MIC90s comparable or superior to control drugs.
• Pharmacokinetics showed dose-dependent maximum plasma concentrations and consistent plasma half-lives, with high urinary excretion rates.
• Clinical efficacy reached 93.9% in evaluated cases, with measurable cerebrospinal fluid concentrations in meningitis patients.

Conclusions:

• Meropenem demonstrates broad-spectrum antibacterial activity and favorable pharmacokinetic properties in pediatric populations.
• The drug achieved significant clinical efficacy, suggesting its potential as a valuable therapeutic option for pediatric infections.
• Further investigation into meropenem's role in treating serious pediatric infections is warranted.